Additional file 2: of Associations of mood symptoms with NYHA functional classes in angina pectoris patients: a cross-sectional study

Table S2. Characteristics of patients stratified by anxiety severity. (DOCX 22 kb

Additional file 3: of Associations of mood symptoms with NYHA functional classes in angina pectoris patients: a cross-sectional study

Table S3. Association between NYHA classes and clinical features using multivariate ordinal logistic regression model. (DOCX 17 kb

Additional file 1: of Associations of mood symptoms with NYHA functional classes in angina pectoris patients: a cross-sectional study

Table S1. Comparison of fit statistics for the five previously hypothesized factor models of PHQ-9. (DOCX 16 kb

Biological markers of stress factors for women in the GDM and control cohorts at fasting and a 1-h OGTT.

<p>Data are means ± SD.</p><p>* Comparison of fasting and 1-h OGTT values of case and control groups, respectively, P < 0.05.</p><p>** Comparison of fasting and 1-h OGTT values of case and control groups, respectively, P < 0.01.</p><p>GDM, gestational diabetes mellitus; OGTT, oral glucose tolerance test; hs-CRP, high-sensitivity C reactive protein; CER, ceruloplasmin; NT, nitrotyrosine; TRF, transferrin; RBC, red blood cell; HGB, hemoglobin; HCT, hematocrit; MCH, mean cell hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean cell volume; RET, reticulocyte; HFR, high fluorescence reticulocytes; MFR, middle fluorescence reticulocytes; LFR, low fluorescence reticulocytes; WBC, white blood cell; MONO, monocyte; NEUT, neutrophil; LYMPH, lymphocyte; PLT, platelets; MPV, mean platelet volume; PDW, red blood cells volume distribution width; PCT, plateletcrit</p><p>Biological markers of stress factors for women in the GDM and control cohorts at fasting and a 1-h OGTT.</p

Correlation between high sugar stress factors and HOMA-IR or HOMA-ISI in women diagnosed as GDM and controls at fasting and a 1-h OGTT.

<p>Data are Spearman's rho.</p><p>* P < 0.05</p><p>** P < 0.01</p><p>HOMA-IR, HOMA insulin resistance index; HOMA-ISI, HOMA insulin sensitivity index; GDM, gestational diabetes mellitus; OGTT, oral glucose tolerance test; hs-CRP, high-sensitivity C reactive protein; CER, ceruloplasmin; NT, nitrotyrosine; TRF, transferrin; RBC, red blood cell; HGB, hemoglobin; HCT, hematocrit; MCH, mean cell hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean cell volume; RET, reticulocyte; HFR, high fluorescence reticulocytes; MFR, middle fluorescence reticulocytes; LFR, low fluorescence reticulocytes; WBC, white blood cell; MONO, monocyte; NEUT, neutrophil; LYMPH, lymphocyte; PLT, platelets; MPV, mean platelet volume; PDW, red blood cells volume distribution width; PCT, plateletcrit</p><p>Correlation between high sugar stress factors and HOMA-IR or HOMA-ISI in women diagnosed as GDM and controls at fasting and a 1-h OGTT.</p

Sociodemographic characteristics of women in the GDM and control cohorts.

<p>* Maternal age, gravidity, parity, BMI and gestational weeks were determined at the time of recruitment. Control subjects were matched against subjects with GDM.</p><p>GDM, gestational diabetes mellitus; BMI, body mass index</p><p>Sociodemographic characteristics of women in the GDM and control cohorts.</p

Insulin secretory capacity and sensitivity of women in the GDM and control cohorts at fasting and a 1-h OGTT.

<p>Data are means ± SD.</p><p>GDM, gestational diabetes mellitus; OGTT, oral glucose tolerance test; HOMA-IR, HOMA insulin resistance index; HOMA-B, HOMA pancreatic β-cell function; HOMA-ISI, HOMA insulin sensitivity index; CIR, corrected insulin response</p><p>Insulin secretory capacity and sensitivity of women in the GDM and control cohorts at fasting and a 1-h OGTT.</p

DataSheet3_Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention: A network meta-analysis of randomized controlled trials.PDF

Aimed to evaluate and compare the interactive effects of different antiplatelet or anticoagulation strategies in patients with chronic coronary syndromes (CCS) after percutaneous coronary intervention (PCI). Randomized controlled trials comparing different antiplatelet or anticoagulant strategies in patients with CCS after PCI were included. The primary outcomes were major adverse cardiovascular event (MACE), mortality, ischemic and bleeding events. Compared to aspirin alone, addition of prasugrel or ticagrelor to aspirin resulted in lower risk of myocardial infarction (MI) [odds ratio (OR): 0.38 (95% confidence interval 0.38–0.62); 0.810–0.84 (0.69–0.98)] and any stroke [0.56 (0.42–0.75)] at the expense of increased risk of major bleeding [1.79 (1.34–2.39); 2.08–2.38 (1.56–3.28)], whereas, clopidogrel monotherapy reduced the risk of any stroke, major bleeding, and intracranial bleeding. On subgroup analysis, compared with aspirin alone, addition of prasugrel resulted in lower MACE [0.72 (0.60–0.86)], MI [0.48 (0.38–0.62)], and stent thrombosis [0.29 (0.09–0.91)], whereas, addition of rivaroxaban 2.5 mg resulted in lower risk of MACE [0.72 (0.60–0.87)], cardiac death [0.71 (0.52–0.98)] and any stroke [0.65 (0.45–0.95)], but not reduced MI. Both prasugrel and rivaroxaban 2.5 mg increased major bleeding [1.79 (1.34–2.39); 1.72 (1.33–2.22)]. Clopidogrel monotherapy was associated with lower MACE [0.72 (0.58–0.90)], any stroke [0.42 (0.24–0.73)], and major bleeding [0.62 (0.40–0.96)]. Adding prasugrel or ticagrelor led to a reduced incidence of MI and prasugrel was also found to reduce the risk of MACE and stent thrombosis in CCS patients with low risk of bleeding after PCI. Clopidogrel monotherapy has advantage in reducing MACE, stroke, and major bleeding events in CCS patients at high risk of bleeding after PCI.Systematic Review Registration:https://clinicaltrials.gov/, PROSPERO Identifier: CRD 42021291050.</p

DataSheet2_Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention: A network meta-analysis of randomized controlled trials.PDF

Aimed to evaluate and compare the interactive effects of different antiplatelet or anticoagulation strategies in patients with chronic coronary syndromes (CCS) after percutaneous coronary intervention (PCI). Randomized controlled trials comparing different antiplatelet or anticoagulant strategies in patients with CCS after PCI were included. The primary outcomes were major adverse cardiovascular event (MACE), mortality, ischemic and bleeding events. Compared to aspirin alone, addition of prasugrel or ticagrelor to aspirin resulted in lower risk of myocardial infarction (MI) [odds ratio (OR): 0.38 (95% confidence interval 0.38–0.62); 0.810–0.84 (0.69–0.98)] and any stroke [0.56 (0.42–0.75)] at the expense of increased risk of major bleeding [1.79 (1.34–2.39); 2.08–2.38 (1.56–3.28)], whereas, clopidogrel monotherapy reduced the risk of any stroke, major bleeding, and intracranial bleeding. On subgroup analysis, compared with aspirin alone, addition of prasugrel resulted in lower MACE [0.72 (0.60–0.86)], MI [0.48 (0.38–0.62)], and stent thrombosis [0.29 (0.09–0.91)], whereas, addition of rivaroxaban 2.5 mg resulted in lower risk of MACE [0.72 (0.60–0.87)], cardiac death [0.71 (0.52–0.98)] and any stroke [0.65 (0.45–0.95)], but not reduced MI. Both prasugrel and rivaroxaban 2.5 mg increased major bleeding [1.79 (1.34–2.39); 1.72 (1.33–2.22)]. Clopidogrel monotherapy was associated with lower MACE [0.72 (0.58–0.90)], any stroke [0.42 (0.24–0.73)], and major bleeding [0.62 (0.40–0.96)]. Adding prasugrel or ticagrelor led to a reduced incidence of MI and prasugrel was also found to reduce the risk of MACE and stent thrombosis in CCS patients with low risk of bleeding after PCI. Clopidogrel monotherapy has advantage in reducing MACE, stroke, and major bleeding events in CCS patients at high risk of bleeding after PCI.Systematic Review Registration:https://clinicaltrials.gov/, PROSPERO Identifier: CRD 42021291050.</p

Presentation1_Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention: A network meta-analysis of randomized controlled trials.pdf

Aimed to evaluate and compare the interactive effects of different antiplatelet or anticoagulation strategies in patients with chronic coronary syndromes (CCS) after percutaneous coronary intervention (PCI). Randomized controlled trials comparing different antiplatelet or anticoagulant strategies in patients with CCS after PCI were included. The primary outcomes were major adverse cardiovascular event (MACE), mortality, ischemic and bleeding events. Compared to aspirin alone, addition of prasugrel or ticagrelor to aspirin resulted in lower risk of myocardial infarction (MI) [odds ratio (OR): 0.38 (95% confidence interval 0.38–0.62); 0.810–0.84 (0.69–0.98)] and any stroke [0.56 (0.42–0.75)] at the expense of increased risk of major bleeding [1.79 (1.34–2.39); 2.08–2.38 (1.56–3.28)], whereas, clopidogrel monotherapy reduced the risk of any stroke, major bleeding, and intracranial bleeding. On subgroup analysis, compared with aspirin alone, addition of prasugrel resulted in lower MACE [0.72 (0.60–0.86)], MI [0.48 (0.38–0.62)], and stent thrombosis [0.29 (0.09–0.91)], whereas, addition of rivaroxaban 2.5 mg resulted in lower risk of MACE [0.72 (0.60–0.87)], cardiac death [0.71 (0.52–0.98)] and any stroke [0.65 (0.45–0.95)], but not reduced MI. Both prasugrel and rivaroxaban 2.5 mg increased major bleeding [1.79 (1.34–2.39); 1.72 (1.33–2.22)]. Clopidogrel monotherapy was associated with lower MACE [0.72 (0.58–0.90)], any stroke [0.42 (0.24–0.73)], and major bleeding [0.62 (0.40–0.96)]. Adding prasugrel or ticagrelor led to a reduced incidence of MI and prasugrel was also found to reduce the risk of MACE and stent thrombosis in CCS patients with low risk of bleeding after PCI. Clopidogrel monotherapy has advantage in reducing MACE, stroke, and major bleeding events in CCS patients at high risk of bleeding after PCI.Systematic Review Registration:https://clinicaltrials.gov/, PROSPERO Identifier: CRD 42021291050.</p